These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Annual zoledronic acid for osteoporosis. BMJ Group Drug Ther Bull; 2008 Dec; 46(12):93-6. PubMed ID: 19056701 [TBL] [Abstract][Full Text] [Related]
7. Compliance with treatment for osteoporosis. Cooper A Lancet; 2006 Nov; 368(9548):1648. PubMed ID: 17098078 [No Abstract] [Full Text] [Related]
8. Intravenous ibandronate (Boniva). Med Lett Drugs Ther; 2006 Aug 14-28; 48(1241-1242):68-9. PubMed ID: 16977282 [No Abstract] [Full Text] [Related]
9. [Osteoporosis and bisphosphonates]. Zuber MA Z Rheumatol; 2007 Dec; 66(8):713-5. PubMed ID: 17955251 [No Abstract] [Full Text] [Related]
10. Is it feasible to adjust bisphosphonate dose according to bone mineral density value in postmenopausal breast cancer patients with bone metastases? Delibasi T; Akkus NI; Altundag O; Pinar T; Altundag K Med Hypotheses; 2006; 66(6):1254-5. PubMed ID: 16413688 [No Abstract] [Full Text] [Related]
11. A once-yearly IV bisphosphonate for osteoporosis. Med Lett Drugs Ther; 2007 Nov; 49(1273):89-90. PubMed ID: 17975523 [No Abstract] [Full Text] [Related]
12. Clinical evaluation of novel bisphosphonate dosing regimens in osteoporosis: the role of comparative studies and implications for future studies. Cosman F; Borges JL; Curiel MD Clin Ther; 2007 Jun; 29(6):1116-27. PubMed ID: 17692726 [TBL] [Abstract][Full Text] [Related]
14. Bisphosphonates: a once-yearly treatment option with Reclast. Van Gilder D S D Med; 2008 Nov; 61(11):416-7. PubMed ID: 19066136 [No Abstract] [Full Text] [Related]
15. [Postmenopausal osteoporosis. Bisphosphonates are not all equal]. MMW Fortschr Med; 2009 Mar; 151(11):46-7. PubMed ID: 19469206 [No Abstract] [Full Text] [Related]
16. [Treating with what? Therapy for how long?]. MMW Fortschr Med; 2005 Dec; 147(51-52):62-3. PubMed ID: 16402713 [No Abstract] [Full Text] [Related]
17. [Adherence to medications for treatment of osteoporosis]. Tanaka I; Oshima H Nihon Rinsho; 2007 Nov; 65 Suppl 9():329-34. PubMed ID: 18161126 [No Abstract] [Full Text] [Related]
18. Yearly zoledronic acid in postmenopausal osteoporosis. Najib MA; Aziz I N Engl J Med; 2007 Aug; 357(7):713; author reply 714-5. PubMed ID: 17703527 [No Abstract] [Full Text] [Related]
19. [Substance properties of zoledronate make it possible: bisphosphonate therapy only once yearly]. MMW Fortschr Med; 2006 Jun; 148(25):60-1. PubMed ID: 16859169 [No Abstract] [Full Text] [Related]
20. Zoledronic acid: new indication. No therapeutic advantage in postmenopausal osteoporosis. Prescrire Int; 2008 Aug; 17(96):143. PubMed ID: 19480098 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]